Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial
- PMID: 26825878
- PMCID: PMC5291548
- DOI: 10.1097/MD.0000000000002237
Comparative Evaluation of Liposomal Albendazole and Tablet-Albendazole Against Hepatic Cystic Echinococcosis: A Non-Randomized Clinical Trial
Abstract
In this study, we aimed to compare the clinical efficacy of liposomal albendazole (L-ABZ) and tablet-albendazole (T-ABZ) for the treatment of human hepatic cystic echinococcosis (CE). Sixty patients with single cyst (CE1) or daughter cyst (CE2) were included in this study and were nonrandomly divided into the L-ABZ group (n = 30, 10 mg/kg per day, p.o., b.i.d.) and T-ABZ group (n = 30, 12-20 mg/kg per day, p.o., b.i.d.), respectively. The treatment duration lasted for 6 months, during which dynamic follow-up was carried out to evaluate the clinical efficacy through calculating the total effective rates (TERs). Measurement data and numerous data were analyzed by the chi-square test. Two-sided tests were performed for all the statistical tests. In our study, 2 patients were lost in the follow-up in the L-ABZ group. One patient was lost in the follow-up in the T-ABZ group, and 1 patient was withdrawal from the study due to receiving surgery. Significant difference was identified in the 3-month TERs of L-ABZ group and T-ABZ group (33.3% vs 76.7%, P < 0.05). Also, remarkable difference was noted in the 6-month TERs in the L-ABZ group and T-ABZ group (66.7% vs 93.3%, P = 0.01). No statistical difference was noticed in the incidence rate of adverse reactions in both groups (P > 0.05). Based on our study, both T-ABZ and L-ABZ are effective for treating human CE. The TER in the L-ABZ group is superior to that of T-ABZ.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Figures



Similar articles
-
[Clinical effect and safety of liposomal-albendazole and tablet-albendazole for the treatment of human cystic echinococcosis].Zhonghua Gan Zang Bing Za Zhi. 2011 Jul;19(7):532-6. doi: 10.3760/cma.j.issn.1007-3418.2011.07.015. Zhonghua Gan Zang Bing Za Zhi. 2011. PMID: 22152246 Clinical Trial. Chinese.
-
Albendazole chemotherapy for human cystic and alveolar echinococcosis in north-western China.Trans R Soc Trop Med Hyg. 1994 May-Jun;88(3):340-3. doi: 10.1016/0035-9203(94)90108-2. Trans R Soc Trop Med Hyg. 1994. PMID: 7974683
-
Effects of albendazole nanoparticles in mice with hepatic echinococosis: Portal vein cannulation versus intravenous administration.Exp Parasitol. 2015 Jul;154:43-6. doi: 10.1016/j.exppara.2015.03.026. Epub 2015 Apr 16. Exp Parasitol. 2015. PMID: 25891538
-
Intra-cystic concentrations of albendazole-sulphoxide in human cystic echinococcosis: a systematic review and analysis of individual patient data.Parasitol Res. 2016 Aug;115(8):2995-3001. doi: 10.1007/s00436-016-5054-x. Epub 2016 Apr 16. Parasitol Res. 2016. PMID: 27085708 Free PMC article.
-
Drug-Induced Liver Failure Requiring Liver Transplant: Report and Review of the Role of Albendazole in Managing Echinococcal Infection.Exp Clin Transplant. 2018 Jun;16(3):344-347. doi: 10.6002/ect.2015.0313. Epub 2016 May 26. Exp Clin Transplant. 2018. PMID: 27228108 Review.
Cited by
-
Efficacy and safety of ultrasound-guided percutaneous microwave ablation for the treatment of hepatic alveolar echinococcosis: A preliminary study.Medicine (Baltimore). 2017 Jul;96(27):e7137. doi: 10.1097/MD.0000000000007137. Medicine (Baltimore). 2017. PMID: 28682866 Free PMC article.
-
Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis.BMC Infect Dis. 2024 Aug 3;24(1):778. doi: 10.1186/s12879-024-09662-w. BMC Infect Dis. 2024. PMID: 39097707 Free PMC article.
-
Preparation and Evaluation of an Oral Administration System of Albendazole-Metal-Organic Framework Based on Dual Response to pH and Enzymes.Pharmaceuticals (Basel). 2025 May 29;18(6):819. doi: 10.3390/ph18060819. Pharmaceuticals (Basel). 2025. PMID: 40573215 Free PMC article.
-
Renovascular Mistaken as Essential Hypertension due to Giant Hepatic Hydatid: A Rare Treatable Entity.Case Rep Med. 2018 Mar 13;2018:9614874. doi: 10.1155/2018/9614874. eCollection 2018. Case Rep Med. 2018. PMID: 29731770 Free PMC article.
-
Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice.Parasitology. 2020 Nov;147(13):1425-1432. doi: 10.1017/S0031182020001225. Epub 2020 Jul 30. Parasitology. 2020. PMID: 32729453 Free PMC article.
References
-
- Torgerson PR, Budke CM. Echinococcosis—an international public health challenge. Res Vet Sci 2003; 74:191–202. - PubMed
-
- Dziri C, Haouet K, Fingerhut A. Treatment of hydatid cyst of the liver: where is the evidence? World J Surg 2004; 28:731–736. - PubMed
-
- Brunetti E, Kern P, Vuitton DA. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1–16. - PubMed
-
- Falagas ME, Bliziotis IA. Albendazole for the treatment of human echinococcosis: a review of comparative clinical trials. Am J Med Sci 2007; 334:171–179. - PubMed
-
- Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997; 64:79–93. - PubMed
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources